The impact of the prevention strategies on the indirect effects of CMV infection in solid organ transplant recipients (Q38193954)

30 August 2017

1 reference

title

The impact of the prevention strategies on the indirect effects of CMV infection in solid organ transplant recipients (English)

1 reference

30 August 2017

Valentín Cuervas-Mons

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24602805%20AND%20SRC:MED&resulttype=core&format=json

Juan Francisco Delgado Jiménez

9 June 2020

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24602805%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

Martin Prieto

16

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24602805%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

18

Antoni Rimola

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24602805%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

author name string

Antonio Roman

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24602805%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

Nicolás Manito

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24602805%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

Josep Maria Campistol

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24602805%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

Luis Almenar

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24602805%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

Manuel Arias

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24602805%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

Fernando Casafont

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24602805%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

Domingo del Castillo

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24602805%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

María G Crespo-Leiro

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24602805%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

J Ignacio Herrero

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24602805%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

Paloma Jara

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24602805%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

José M Morales

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24602805%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

Mercedes Navarro

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24602805%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

Federico Oppenheimer

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24602805%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

Luis A Pulpón

17

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24602805%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

Daniel Serón

19

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24602805%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

Piedad Ussetti

20

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24602805%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

ATOS working group

21

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24602805%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

publication date

27 January 2014

1 reference

30 August 2017

Transplantation Reviews

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24602805%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

volume

28

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24602805%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

page(s)

84-91

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24602805%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24602805%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2014.01.001

GESITRA-SEIMC/REIPI recommendations for the management of cytomegalovirus infection in solid-organ transplant patients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2014.01.001

Etiology and impact of cytomegalovirus disease on solid organ transplant recipients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2014.01.001

Assessment of cytomegalovirus-specific cell-mediated immunity for the prediction of cytomegalovirus disease in high-risk solid-organ transplant recipients: a multicenter cohort study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2014.01.001

Cytomegalovirus infection in organ-transplant recipients: diagnostic value of pp65 antigen test, qualitative polymerase chain reaction (PCR) and quantitative Taqman PCR.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2014.01.001

Monitoring human cytomegalovirus infection in transplant recipients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2014.01.001

Infection in organ-transplant recipients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2014.01.001

Age-dependent association between low frequency of CD27/CD28 expression on pp65 CD8+ T cells and cytomegalovirus replication after transplantation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2014.01.001

The impact of cytomegalovirus infection and disease on rejection episodes in renal allograft recipients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2014.01.001

Reassessing the impact of cytomegalovirus infection in kidney and kidney-pancreas transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2014.01.001

Cytomegalovirus infection--an etiological factor for rejection? A prospective study in 242 renal transplant patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2014.01.001

Cytomegalovirus: occurrence, severity, and effect on graft survival in simultaneous pancreas-kidney transplantation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2014.01.001

Acute rejection episodes in pediatric renal transplant recipients with cytomegalovirus infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2014.01.001

Influence of cytomegalovirus disease on early and late renal graft function.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2014.01.001

Effect of cytomegalovirus viremia on subclinical rejection or interstitial fibrosis and tubular atrophy in protocol biopsy at 3 months in renal allograft recipients managed by preemptive therapy or antiviral prophylaxis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2014.01.001

Association between cytomegalovirus disease and chronic rejection in kidney transplant recipients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2014.01.001

Significance of cytomegalovirus infection in renal transplantation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2014.01.001

Intragraft cytomegalovirus protein expression is associated with reduced renal allograft survival.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2014.01.001

The association of viral infection and chronic allograft nephropathy with graft dysfunction after renal transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2014.01.001

Cytomegalovirus infection and graft rejection in renal transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2014.01.001

Cytomegalovirus disease after prophylaxis with oral ganciclovir in renal transplantation: the importance of HLA-DR matching

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2014.01.001

Persistent cytomegalovirus infection in kidney allografts is associated with inferior graft function and survival

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2014.01.001

The impact of cytomegalovirus infection ≥1 year after primary renal transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2014.01.001

Impact of early cytomegalovirus infection and disease on long-term recipient and kidney graft survival

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2014.01.001

Cytomegalovirus infection in renal transplant recipients is associated with impaired survival irrespective of expected mortality risk

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2014.01.001

Association of cytomegalovirus disease and acute rejection with graft loss in kidney transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2014.01.001

The association between cytomegalovirus infection and atherosclerotic events in renal transplant recipients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2014.01.001

Cytomegalovirus replication and "herpesvirus burden" as risk factor of cardiovascular events in the first year after renal transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2014.01.001

Increased incidence of cardiac complications in kidney transplant recipients with cytomegalovirus disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2014.01.001

Asymptomatic cytomegalovirus infection is associated with increased risk of new-onset diabetes mellitus and impaired insulin release after renal transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2014.01.001

Determinants of insulin secretion after renal transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2014.01.001

The influence of cytomegalovirus infections on patient and renal graft outcome: a 3-year, multicenter, observational study (Post-ECTAZ Study).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2014.01.001

An association between cytomegalovirus infection and chronic rejection after liver transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2014.01.001

Impact of cytomegalovirus infection, year of transplantation, and donor age on outcomes after liver transplantation for hepatitis C.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2014.01.001

The pathogenesis of hepatitis C virus is influenced by cytomegalovirus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2014.01.001

Cytomegalovirus Disease as a Risk Factor for Graft Loss and Death After Orthotopic Liver Transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2014.01.001

Significance of cytomegalovirus for long-term survival after orthotopic liver transplantation: a prospective derivation and validation cohort analysis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2014.01.001

Association of cytomegalovirus infection and disease with death and graft loss after liver transplant in high-risk recipients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2014.01.001

Is cytomegalovirus infection dangerous in cytomegalovirus-seropositive recipients after liver transplantation?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2014.01.001

Lack of association between cytomegalovirus infection, HLA matching and the vanishing bile duct syndrome after liver transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2014.01.001

Progression of liver fibrosis in patients with chronic hepatitis C after orthotopic liver transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2014.01.001

Posttransplant diabetes mellitus in liver transplant recipients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2014.01.001

Posttransplant lymphoproliferative disease in primary Epstein-Barr virus infection after liver transplantation: the role of cytomegalovirus disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2014.01.001

Cytomegalovirus infection status predicts progression of heart-transplant vasculopathy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2014.01.001

Cytomegalovirus infection is associated with cardiac allograft rejection and atherosclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2014.01.001

Relevance of cytomegalovirus infection and coronary-artery remodeling in the first year after heart transplantation: a prospective three-dimensional intravascular ultrasound study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2014.01.001

Positive pretransplantation cytomegalovirus serology is a risk factor for cardiac allograft vasculopathy in children.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2014.01.001

Cytomegalovirus infection in heart transplant recipients is associated with impaired endothelial function

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2014.01.001

Determinants of cardiovascular mortality after renal transplantation: a role for cytomegalovirus?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2014.01.001

Endothelial Dysfunction and Cytomegalovirus Replication in Pediatric Heart Transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2014.01.001

Cytomegalovirus infection impairs the nitric oxide synthase pathway: role of asymmetric dimethylarginine in transplant arteriosclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2014.01.001

Predictors of renal dysfunction at 1 year in heart transplant patients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2014.01.001

Constrictive (obliterative) bronchiolitis: diagnosis, etiology, and a critical review of the literature

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2014.01.001

Bronchiolitis obliterans syndrome and early human cytomegalovirus DNAaemia dynamics after lung transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2014.01.001

Cytomegalovirus serologic status and postoperative infection correlated with risk of developing chronic rejection after pulmonary transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2014.01.001

Sequelae of cytomegalovirus pulmonary infections in lung allograft recipients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2014.01.001

Risk factors for the development of bronchiolitis obliterans syndrome after lung transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2014.01.001

Cytomegalovirus Replication Within the Lung Allograft Is Associated With Bronchiolitis Obliterans Syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2014.01.001

Cytomegalovirus and long-term outcome after lung transplantation in Gothenburg, Sweden.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2014.01.001

Cytomegalovirus viremia associated with death or retransplantation in pediatric lung-transplant recipients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2014.01.001

Cytomegalovirus DNA load patterns developing after lung transplantation are significantly correlated with long-term patient survival

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2014.01.001

Cytomegalovirus-induced immunopathology and its clinical consequences

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2014.01.001

Immunobiology of human cytomegalovirus: from bench to bedside.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2014.01.001

Cytomegalovirus in transplantation - challenging the status quo.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2014.01.001

The 'indirect' effects of cytomegalovirus infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2014.01.001

Acceleration of allograft failure by cytomegalovirus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2014.01.001

Does cytomegalovirus play a causative role in the development of various inflammatory diseases and cancer?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2014.01.001

Human cytomegalovirus targets different subsets of antigen-presenting cells with pathological consequences for host immunity: implications for immunosuppression, chronic inflammation and autoimmunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2014.01.001

Cytomegalovirus-induced gammadelta T cells associate with reduced cancer risk after kidney transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2014.01.001

Impact of prophylactic versus preemptive valganciclovir on long-term renal allograft outcomes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2014.01.001

Meta-analysis: the efficacy of strategies to prevent organ disease by cytomegalovirus in solid organ transplant recipients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2014.01.001

Antiviral medications to prevent cytomegalovirus disease and early death in recipients of solid-organ transplants: a systematic review of randomised controlled trials.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2014.01.001

Cytomegalovirus prophylaxis and graft outcome in solid organ transplantation: a collaborative transplant study report

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2014.01.001

Improvement in long-term renal graft survival due to CMV prophylaxis with oral ganciclovir: results of a randomized clinical trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2014.01.001

The efficacy and safety of 200 days valganciclovir cytomegalovirus prophylaxis in high-risk kidney transplant recipients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2014.01.001

Use of high-dose ganciclovir for the treatment of cytomegalovirus replication in solid organ transplant patients with ganciclovir resistance-inducing mutations.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2014.01.001

Randomized controlled trial of oral ganciclovir versus oral acyclovir after induction with intravenous ganciclovir for long-term prophylaxis of cytomegalovirus disease in cytomegalovirus-seropositive liver transplant recipients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2014.01.001

Increased incidence of cytomegalovirus infection in high-risk liver transplant recipients receiving valganciclovir prophylaxis versus ganciclovir prophylaxis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2014.01.001

Indirect outcomes associated with cytomegalovirus (opportunistic infections, hepatitis C virus sequelae, and mortality) in liver-transplant recipients with the use of preemptive therapy for 13 years

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2014.01.001

Risk factors associated with cytomegalovirus infection in heart transplant patients: a prospective, epidemiological study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2014.01.001

Impact of prophylactic immediate posttransplant ganciclovir on development of transplant atherosclerosis: a post hoc analysis of a randomized, placebo-controlled study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2014.01.001

Acute rejection and cardiac allograft vascular disease is reduced by suppression of subclinical cytomegalovirus infection.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2014.01.001

Prophylaxis versus preemptive anti-cytomegalovirus approach for prevention of allograft vasculopathy in heart transplant recipients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2014.01.001

Risk factors for bronchiolitis obliterans: a systematic review of recent publications

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2014.01.001

Efficacy and cost effectiveness of oral ganciclovir in the prevention of cytomegalovirus disease after lung transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2014.01.001

Lack of association between beta-herpesvirus infection and bronchiolitis obliterans syndrome in lung transplant recipients in the era of antiviral prophylaxis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2014.01.001

Combined CMV Prophylaxis Improves Outcome and Reduces the Risk for Bronchiolitis Obliterans Syndrome (BOS) after Lung Transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2014.01.001

Combined cytomegalovirus prophylaxis in lung transplantation: effects on acute rejection, lymphocytic bronchitis/bronchiolitis, and herpesvirus infections.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2014.01.001

Ganciclovir/valganciclovir prophylaxis decreases cytomegalovirus-related events and bronchiolitis obliterans syndrome after lung transplantation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2014.01.001

Ganciclovir for cytomegalovirus: a call for indefinite prophylaxis in lung transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2014.01.001

Immune-based therapies for cytomegalovirus infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2014.01.001

Cytomegalovirus glycoprotein-B vaccine with MF59 adjuvant in transplant recipients: a phase 2 randomised placebo-controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2014.01.001

Complications, diagnosis, management, and prevention of CMV infections: current and future

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2014.01.001

Management of cytomegalovirus infection in solid organ transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2014.01.001